Vanda Pharma receives Israeli marketing nod for Fanapt to treat schizophrenia
The Israeli Ministry of Health (MoH) has granted marketing approval for Vanda Pharmaceuticals' Fanapt for the treatment of schizophrenia.
Vanda will commercialize Fanapt in Israel through its partner Megapharm Ltd., a leading private biotech, pharmaceutical and medical nutrition marketing companies in Israel.
Fanapt tablets are indicated for the treatment of adults with schizophrenia.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.